Portal de Periódicos da CAPES

Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions

2007; Elsevier BV; Volume: 50; Issue: 5 Linguagem: Inglês

10.1016/j.jacc.2007.06.002

1558-3597

Lisette Okkels Jensen, Michael Mæng, Anne Kaltoft, Per Thayssen, Hans Henrik Tilsted Hansen, Morten Bøttcher, Jens Flensted Lassen, Lars Romer Krussel, Klaus Rasmussen, Knud Noerregaard Hansen, Lars Pedersen, Søren Paaske Johnsen, Henrik Toft Sørensen, Leif Thuesen,

Antiplatelet Therapy and Cardiovascular Diseases

The aim of the study was to examine outcomes subsequent to implantation of drug-eluting stents (DES) and bare-metal stents (BMS). Use of DES might be associated with increased risk of stent thrombosis (ST), myocardial infarction (MI), and death. From January 2002 through June 2005, data from all percutaneous coronary interventions in western Denmark were prospectively recorded in the Western Denmark Heart Registry; 12,395 consecutive patients (17,152 lesions) treated with stent implantation were followed for 15 months. Data on death and MI were ascertained from the national databases. The Academic Research Consortium definition of ST was used. The DES were implanted in 3,548 patients (5,422 lesions) and BMS were implanted in 8,847 patients (11,730 lesions). Definite, probable, or possible ST was found in 190 (2.15%) patients in the BMS group and in 64 (1.80%) patients in the DES. The risk of definite ST was similar in the 2 groups (DES: 0.65%; BMS: 0.61%). Very late definite ST (between 12 and 15 months after implantation) occurred more frequently in patients receiving DES (hazard ratio [HR] 10.93, 95% confidence interval [CI] 1.27 to 93.76). Also, the risk of MI between 12 and 15 months after implantation was higher in the DES group (HR 4.00, 95% CI 2.06 to 7.79). Mortality was similar in the 2 groups. Target lesion revascularization was reduced by 43% in patients treated with DES (HR 0.57, 95% CI 0.48 to 0.67). The minor risk of ST and MI within 15 months after implantation of DES seems unlikely to outweigh the benefit of these stents.